Healthcare commercialization services company PDI has rebuffed an acquisition offer from nuclear medicine firm Digirad.
Digirad announced on October 29 that it sent a letter to PDI offering to buy the firm for a combination of cash and Digirad stock. The deal would be accomplished through a merger agreement, after due diligence, according to Digirad.
However, the chair of PDI's board, Gerald Belle, said the firm is not for sale and does not consider the Digirad bid to be a meaningful offer.
